Schonfeld Strategic Advisors LLC Has $14.41 Million Stock Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Schonfeld Strategic Advisors LLC lifted its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 129.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 849,081 shares of the biotechnology company's stock after purchasing an additional 479,482 shares during the quarter. Schonfeld Strategic Advisors LLC owned approximately 3.13% of Arcturus Therapeutics worth $14,409,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Northern Trust Corp raised its holdings in Arcturus Therapeutics by 5.6% during the fourth quarter. Northern Trust Corp now owns 256,332 shares of the biotechnology company's stock valued at $4,350,000 after buying an additional 13,582 shares in the last quarter. Boothbay Fund Management LLC acquired a new stake in Arcturus Therapeutics in the 4th quarter worth approximately $1,000,000. Virtus ETF Advisers LLC lifted its holdings in Arcturus Therapeutics by 38.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company's stock worth $69,000 after purchasing an additional 1,132 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Arcturus Therapeutics by 7.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 19,018 shares of the biotechnology company's stock valued at $323,000 after purchasing an additional 1,279 shares during the last quarter. Finally, MGO One Seven LLC lifted its stake in shares of Arcturus Therapeutics by 5.6% in the fourth quarter. MGO One Seven LLC now owns 41,350 shares of the biotechnology company's stock worth $702,000 after buying an additional 2,204 shares during the last quarter. Institutional investors own 94.54% of the company's stock.

Arcturus Therapeutics Stock Performance

NASDAQ ARCT traded up $0.33 during trading on Friday, reaching $12.83. 240,286 shares of the company traded hands, compared to its average volume of 449,659. The stock's 50 day moving average price is $12.35 and its two-hundred day moving average price is $15.77. Arcturus Therapeutics Holdings Inc. has a 1-year low of $8.04 and a 1-year high of $45.00. The company has a market cap of $347.96 million, a price-to-earnings ratio of -5.78 and a beta of 3.41.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.78). The business had revenue of $22.77 million during the quarter, compared to analyst estimates of $44.64 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. Equities research analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. HC Wainwright restated a "buy" rating and set a $60.00 price target on shares of Arcturus Therapeutics in a report on Thursday, April 10th. Wells Fargo & Company lowered their target price on Arcturus Therapeutics from $58.00 to $50.00 and set an "overweight" rating on the stock in a report on Friday, March 7th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arcturus Therapeutics in a report on Friday, March 7th. BTIG Research set a $48.00 target price on shares of Arcturus Therapeutics and gave the stock a "buy" rating in a research report on Monday, March 10th. Finally, Canaccord Genuity Group decreased their price target on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a "buy" rating on the stock in a research report on Monday, March 10th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Arcturus Therapeutics presently has an average rating of "Buy" and an average target price of $59.20.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.